Clinical Trial Search

Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment — -15.84; -14.85; -13.81 scores on a scale — p=0.1031

Primary: Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit). — 100; 99.02; 99.14; 98.51 Percentage of participants

Primary: FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12 — 0.297; 0.191 Area Under the Curve (L) (standardized) — p=<.0001

Primary: Clinician Administered PTSD Scale (Pre & Posttreatment) — 30.0; 53.6 units on a scale

Primary: Pain 30 Minutes — 5.5; 6.2 units on a scale — p=0.386

Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844

Primary: Change in Glycemic Control (HbA1c) — 8.02; 7.93; 7.73; 8.22 percent HbA1c — p=0.004

Primary: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks — -7.3; -6.8 units on a scale — p=0.583

Primary: Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response — 67.5; 74.9; 73.9; 67.4 Percentage of participants

Primary: PTSD Symptom Severity — 31.4; 31.5; 30.2; 29.9 units on a scale

Primary: Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48 — 59.0; 57.8 percentage of participants

Primary: Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24 — 2.98 score on a scale — p=<0.001

Primary: BFI Score — 65.0; 57.2; 48.8; 41.5 units on a scale — p=0.289

Primary: Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels) — 83; 86.4 percentage change from baseline

Primary: Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 12 — 31.47; 31.92 gramm per liter (g/L)